Given that c-Myc is crucial for HCC development and progression regardless of the etiology of disease and that MLs already have been tested in clinical trials for various tumors, our findings suggest that Fraxini could be a potentially efficacious treatment for patients with advanced HCC or with overexpression of CMYC gene. This evidence concerns the gene MYC and hepatocellular carcinoma.